Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

Paris, France, and Cambridge, Massachusetts (USA) Apr. 4 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that Hensify® (NBTXR3) has obtained a CE mark for the treatment of locally-advanced soft tissue sarcoma (“STS”).  Hensify® is the brand name for NBTXR3 [...]